Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma

Oncogene volume 33, pages 5319–5331 (2014)Cite this article

Subjects

Abstract

We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused very low levels in MPM cell lines and specimens. Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via specific binding to its 3′-UTR. Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells. In line with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on clonogenicity and replicative senescence. This further supports the relevance of the mir-145-OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced senescence and that induced by the re-expression of mir-145 are discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Kaufman AJ, Pass HI . Current concepts in malignant pleural mesothelioma. Expert Review Anticancer Ther 2008; 8: 293–303.

    Article  CAS  Google Scholar 

  2. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physio 2012; 227: 44–58.

    Article  CAS  Google Scholar 

  3. Hazarika M, White RM Jr., Booth BP, Wang YC, Ham DY, Liang CY et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: 982–992.

    CAS  PubMed  Google Scholar 

  4. Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ . Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiov Sur 2010; 140: 352–355.

    Article  CAS  Google Scholar 

  5. Tang G, Tang X, Mendu V, Tang X, Jia X, Chen QJ et al. The art of microRNA: various strategies leading to gene silencing via an ancient pathway. Biochimica et biophysica acta 2008; 1779: 655–662.

    Article  CAS  PubMed  Google Scholar 

  6. Ji X . The mechanism of RNase III action: how dicer dices. Curr Top Microbiol 2008; 320: 99–116.

    CAS  Google Scholar 

  7. Deng S, Calin GA, Croce CM, Coukos G, Zhang L . Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008; 7: 2643–2646.

    Article  CAS  PubMed  Google Scholar 

  8. Calin GA, Garzon R, Cimmino A, Fabbri M, Croce CM . MicroRNAs and leukemias: how strong is the connection? Leukemia Res 2006; 30: 653–655.

    Article  CAS  Google Scholar 

  9. Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866.

    Article  CAS  PubMed  Google Scholar 

  10. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010; 70: 1916–1924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013; 132: 2479–2491.

    Article  CAS  PubMed  Google Scholar 

  12. Adammek M, Greve B, Kassens N, Schneider C, Bruggemann K, Schuring AN et al. MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors. Fertil Steril 2013; 99: 1346–1355.

    Article  CAS  PubMed  Google Scholar 

  13. Wu Y, Liu S, Xin H, Jiang J, Younglai E, Sun S et al. Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 2011; 117: 3989–3998.

    Article  CAS  PubMed  Google Scholar 

  14. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166–1176.

    CAS  PubMed  Google Scholar 

  15. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS . MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137: 647–658.

    Article  CAS  PubMed  Google Scholar 

  16. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem cells and development 2009; 18: 1093–1108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Samardzija C, Quinn M, Findlay JK, Ahmed N . Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. Journal of ovarian research 2012; 5: 37.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012; 31: 4898–4911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY . Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 621–628.

    Article  CAS  PubMed  Google Scholar 

  20. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R et al. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes & cancer 2010; 1: 908–916.

    Article  CAS  Google Scholar 

  21. Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y et al. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 2009; 57: 724–733.

    Article  PubMed  Google Scholar 

  22. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433–10444.

    Article  CAS  PubMed  Google Scholar 

  23. Dai X, Ge J, Wang X, Qian X, Zhang C, Li X . OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol Rep 2013; 29: 155–160.

    Article  CAS  PubMed  Google Scholar 

  24. Peng S, Maihle NJ, Huang Y . Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 2010; 29: 2153–2159.

    Article  CAS  PubMed  Google Scholar 

  25. Rudd RM . Malignant mesothelioma. Brit Med Bull 2010; 93: 105–123.

    Article  CAS  PubMed  Google Scholar 

  26. Casarsa C, Bassani N, Ambrogi F, Zabucchi G, Boracchi P, Biganzoli E et al. Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett 2011; 302: 136–143.

    Article  CAS  PubMed  Google Scholar 

  27. Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. European journal of cardio-thoracic surgery. official journal of the European Association for Cardio-thoracic Surgery 2010; 37: 566–572.

    Article  Google Scholar 

  28. Freund A, Laberge RM, Demaria M, Campisi J . Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell 2012; 23: 2066–2075.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006; 126: 503–514.

    Article  CAS  PubMed  Google Scholar 

  30. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113: 703–716.

    Article  CAS  PubMed  Google Scholar 

  31. Romanov VS, Pospelov VA, Pospelova TV . Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochemistry Biokhimiia 2012; 77: 575–584.

    Article  CAS  PubMed  Google Scholar 

  32. Wajapeyee N, Deibler SK, Green MR . Genome-wide RNAi screening to identify regulators of oncogene-induced cellular senescence. Methods Mol Biol 2013; 965: 373–382.

    Article  CAS  PubMed  Google Scholar 

  33. Weinberg WC, Denning MF . P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 2002; 13: 453–464.

    Article  PubMed  Google Scholar 

  34. Kai K, D'Costa S, Yoon BI, Brody AR, Sills RC, Kim Y . Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer 2010; 70: 146–151.

    Article  PubMed  Google Scholar 

  35. Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene 2012; 31: 3148–3163.

    Article  CAS  PubMed  Google Scholar 

  36. Yilmaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Metast Rev 2009; 28: 15–33.

    Google Scholar 

  37. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell stem cell 2010; 7: 618–630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP et al. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2011; 13: R94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Granville L, Laga AC, Allen TC, Dishop M, Roggli VL, Churg A et al. Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. Arch Pathol Lab Med 2005; 129: 1428–1443.

    PubMed  Google Scholar 

  40. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC . Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 2012; 136: 277–293.

    Article  CAS  PubMed  Google Scholar 

  41. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT . Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013; 32: 61–69.

    Article  PubMed  Google Scholar 

  42. Lu Y, Chopp M, Zheng X, Katakowski M, Buller B, Jiang F . MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncology reports 2013; 29: 67–72.

    Article  PubMed  Google Scholar 

  43. Lee HK, Bier A, Cazacu S, Finniss S, Xiang C, Twito H et al. MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor. PloS One 2013; 8: e54652.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 2012; 3: 723–734.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM et al. Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells. Mol Cancer Ther 2011; 10: 2062–2071.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zhang J, Guo H, Qian G, Ge S, Ji H, Hu X et al. MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer 2010; 9: 211.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Canc Res 2010; 29: 151.

    Article  Google Scholar 

  48. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34: 1461–1466.

    CAS  PubMed  Google Scholar 

  49. Bonifacio LN, Jarstfer MB . MiRNA profile associated with replicative senescence, extended cell culture, and ectopic telomerase expression in human foreskin fibroblasts. PLoS One 2010; 5: pii:e12519.

    Article  Google Scholar 

  50. Basu D, Reyes-Mugica M, Rebbaa A . Role of the beta catenin destruction complex in mediating chemotherapy-induced senescence-associated secretory phenotype. PLoS One 2012; 7: e52188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Cahu J, Bustany S, Sola B . Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell death & disease 2012; 3: e446.

  52. Rodier F . Detection of the senescence-associated secretory phenotype (SASP). Methods Mol Biol 2013; 965: 165–173.

    Article  CAS  PubMed  Google Scholar 

  53. Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Oncol 2012; 19 (Suppl 3): S656–S664.

    Article  Google Scholar 

  54. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Cell Biol 2011; 22: 1686–1698.

    Article  CAS  Google Scholar 

  55. Gregory PA, Bracken CP, Bert AG, Goodall GJ . MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008; 7: 3112–3118.

    Article  CAS  PubMed  Google Scholar 

  56. Ceppi P, Peter ME . MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene 2014; 33: 269–278.

    Article  CAS  PubMed  Google Scholar 

  57. Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 2014; 33: 702–712.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge INAIL (Italian Workers' Compensation Authority) for grant support (to GB).

Author information

Author notes

  1. M Cioce and F Ganci: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, USA

    M Cioce, C Canino & H I Pass

  2. Translational Oncogenomic Unit, Italian National Cancer Institute ‘Regina Elena’, Rome, Italy

    F Ganci, V Canu, A Sacconi, E Korita & G Blandino

  3. Molecular Chemoprevention Group, Italian National Cancer Institute ‘Regina Elena’, Rome, Italy

    F Mori & S Strano

  4. Department of Pathology Italian National Cancer Institute, Rome, Italy

    B Casini, M A Carosi & P Visca

  5. Unit of Thoracic Surgery, Regina Elena National Cancer Institute, Rome, Italy

    G Alessandrini & F Facciolo

  6. Department of Surgical Oncology San Vincenzo Hospital, Taormina, Italy

    A Cambria, R Blandino & V Panebianco

  7. Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

    S Volinia & C M Croce

  8. Department of Oncology, McMaster University, Hamilton, ON, Canada

    P Muti

Authors
  1. M Cioce
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Ganci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Canu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Sacconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Canino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Korita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Casini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Alessandrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Cambria
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M A Carosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Blandino
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. V Panebianco
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F Facciolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P Visca
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Volinia
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. P Muti
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. S Strano
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. C M Croce
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. H I Pass
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. G Blandino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Blandino.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cioce, M., Ganci, F., Canu, V. et al. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 33, 5319–5331 (2014). https://doi.org/10.1038/onc.2013.476

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.476

Keywords

This article is cited by

Search

Advanced search

Quick links